Kevin Wright | Authors


Promising Results Seen With Pembrolizumab Plus Chemoradiation in Stage III NSCLC

January 29, 2021

Antitumor activity was seen in the combination of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer, regardless of PD-L1 status or tumor histology.

Pembrolizumab Plus Lanreotide Induces High Response Rates in GEP Neuroendocrine Tumors

January 15, 2021

Roughly 40% of patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors treated with pembrolizumab in combination with lanreotide achieved stable disease, according to results from the phase 1b/2 PLANET clinical trial presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancer Symposium.

Selinexor Demonstrates Significant Benefit in Pretreated Multiple Myeloma as Once Weekly Regimen

December 05, 2020

Treatment with selinexor, bortezomib, and dexamethasone demonstrated an increase in overall response rate and progression-free survival in patients with multiple myeloma and high cytogenetic risk despite a dosing schedule that utilized 40% less bortezomib and 25% less dexamethasone during the first 24 weeks of treatment.

Olaparib Treatment Leads to Significant Survival Improvement in Patients with mCRPC

December 04, 2020

A significantly longer overall survival was observed with olaparib in patients with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM, compared with those who received enzalutamide or abiraterone plus prednisone, according to research presented at the 21st Annual Meeting of the Society of Urologic Oncology.

Apalutimide Combo Significantly Improves Survival Outcomes in nmCRPC

May 30, 2020

Apalutimide in combination with androgen deprivation therapy led to a significant improvement in overall survival in patients with nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN clinical trial.